Mendiola-Pastrana IR, Urbina-Aranda II, Muñoz-Simón AE, Juanico-Morales G, López-Ortiz G

Language: Spanish
References: 22
Page: 22-26
PDF size: 190.55 Kb.

ABSTRACT

Objective: to evaluate the performance of the Finnish Diabetes Risk Score (findrisc) as a diabetes mellitus type 2 (DM2) screening test. Methods: validation study of diagnostic test. 295 participants without diagnosis of DM2, who were attending a Family Medicine Unit in Acapulco, Guerrero, Mexico, were selected using a simple random sampling. The findrisc was applied to rate the development of DM2 risk level. A fasting glucose test was taken as an important standard to diagnose DM2. The Mantel and Haenszel χ² test and or calculation were performed to measure the association and the magnitude, as well as sensitivity, specificity and predictive values to evaluate the performance of the questionnaire. Results: it was determined that 156 patients (52.84%) had high risk to develop DM2, 35 of them were diagnosed with DM2 and 49 with pre-diabetes. Patients with low-risk, 26 had pre-diabetes and 5 DM2. A ≥15 score by findrisc was associated with altered fasting glucose ≥100mg/dl (or: 4.06, p=0.0001), pre-diabetes (or: 2.82, p=0.0002) and DM2 (or: 7.75, p=0.0001). The sensitivity and specificity of the questionnaire for the DM2 diagnosis was 87.50% and 52.55% respectively, with 95% ic statistically significant. Conclusion: the findrisc is a tool that potentially can be used for the DM2 screening in the Mexican population, it is practical, simple, fast, non-invasive, and economic and it can be used in daily practice of the family physician.

REFERENCES

1. Instituto Mexicano del Seguro Social. Tratamiento de la diabetes mellitus tipo 2 en el primer nivel de atención. México; 2014. 1-136.

2. Soriguer F, Valdés S, Tapia MJ, Esteva I, Ruiz MS, Almaraz MC, et al. Validación del findrisc (Finnish Diabetes Risk SCore) para la predicción del riesgo de diabetes tipo 2 en una población del sur de España. Estudio Pizarra. Med Clin (Barc). 2012;138(9):371-6.

3. Salinero M, Carrillo E, Abánades J, Dujovne I, Cárdenas J. Riesgo basal de Diabetes Mellitus en Atención Primaria según cuestionario findrisc, factores asociados y evolución clínica tras 18 meses de seguimiento. Rev Clin Esp. 2010;210(9):448- 53.

4. Secretaría de Salud. Diagnóstico, Metas de Control Ambulatorio y Referencia Oportuna de Prediabetes y Diabetes Mellitus Tipo 2 en Adultos en el Primer Nivel de Atención. México: ssa; 2013. 1-110.

5. Instituto Nacional de Salud Pública. Encuesta Nacional de Salud y Nutrición MC 2016 [Internet]. 2012; [citado 2017 Ago 15]. Disponible en: http:// promocion.salud.gob.mx/dgps/descargas1/doctos_ 2016/ensanut_mc_2016-310oct.pdf

6. American Diabetes Association (ada). Standard of medical care in diabetes - 2017. Diabetes Care. 2017;40(sup 1):s4-128.

7. Salinero M, De Burgos C, Mostaza J, Lahoz C, Abánades JC, Gómez P, et al. Validating prediction scales of type 2 diabetes mellitus in Spain: the spredia- 2 population-based prospective cohort study protocol. bmj Open. 2015;5(7):1-10.

8. Winkler G, Hídvégi T, Vándorfi G, Balogh S, Jermendy G. Prevalence of undiagnosed abnormal glucose tolerance in adult patients cared for by general practitioners in Hungary. Results of a riskstratified screening based on findrisc questionnaire. Med Sci Monit. 2013;19:67-72.

9. Waugh N, Shyangdan D, Taylor S, Suri G, Hall B. Screening for type 2 diabetes: A short report for the National Screening Committee. Health Technol Assess (Rockv). 2013;17(35):1-89.

10. Hernández EC, Salazar MC, Juárez MOC. Guía Técnica Para La Atención De Mujeres de 20 a 59 años de edad. 10a ed. México: imss, Programas Integrados de Salud; 2010. 1-50.

11. Hernández EC, Salazar MC, Juárez MOC. Guía Técnica Para la Atención de Adultos Mayores de 60 años. 10a ed. México: imss, Programas Integrados de Salud; 2010. 1-50.

12. Hernández EC, Salazar MC, Juárez MOC. Guía Técnica Para la Atención de Hombres de 20 a 59 Años de Edad. 10a ed. México: imss, Programas Integrados de Salud; 2010. 1-50.

13. Rathmann W, Martin S, Haastert B, Icks A, Holle R, Lowel H, et al. Performance of screening questionnaires and risk scores for undiagnosed diabetes: the kora Survey 2000. Arch Intern Med. 2005;165(4):436-41.

14. Franciosi M, De Berardis G, Rossi M, Sacco M, Belfiglio M, Pellegrini F, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: The igloo (impaired glucose tolerance and long-term outcomes observational) study. Diabetes Care. 2005;28(5):1187-94.

15. Zhang Y, Hu G, Zhang L, Mayo R, Chen L. A Novel Testing Model For Opportunistic Screening of Pre-diabetes and Diabetes Among U.S. Adults. PLoS One. 2015;10(3):1-14.

16. Tuomilehto J, Lindstrom J. Screening for Type 2 Diabetes in the Adult Population. Can Task Force Prev Health Care. 2012;1-2.

17. Lindström J, Tuomilehto J. The Diabetes Risk Score. A practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725-31.

18. Zhang L, Zhang Z, Zhang Y, Hu G, Chen L. Evaluation of Finnish diabetes risk score in screening undiagnosed diabetes and prediabetes among U.S. adults by gender and race: nhanes 1999-2010. PLoS One. 2014;9(5): e97865.

19. Janghorbani M, Adineh H, Amini M. Evaluation of the Finnish Diabetes Risk Score (findrisc) as a screening tool for the metabolic syndrome. Rev Diabet Stud. 2013;10(1):283-92.

20. Gomez D, Alvarado L, Ayala M, Forero L, Camacho P, Lopez P. Evaluation of the Finnish Diabetes Risk Score to predict type 2 diabetes mellitus in a Colombian population: A longitudinal observational study. World J Diabetes. 2015;6(17):1337-44.

21. Fenn N. Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Acad Emerg Med. 1996;3(9):895-900.

22. Schwarz P, Li J, Lindstrom J, Tuomilehto J. Tools for predicting the risk of type 2 diabetes in daily practice. Horm Metab Res. 2009;41(2):86-97.